Summary
The Translational Research Network for Prostate Cancer (TransPot) program adopts an innovative, multidisciplinary approach, providing highly sought-after, effective solutions for incurable prostate cancer (PC).
The TransPot scientific objective is to obtain an unmatched depth of molecular, mechanistic and informatics systems-level disease understanding in order to improve the prognosis and treatment of lethal PC, aimed to (i) provide important insights into molecular mechanisms driving treatment resistant PC including castrate-resistant PC (CRPC), (ii) identify novel therapeutic targets, (iii) develop and validate predictive models for disease progression, prognosis and responsiveness to current and novel (co-)treatment options, and (iv) provide superior, clinically relevant tools and biomarker signatures for personalising and optimising CRPC therapy.
Our research program is built on network-wide, state-of-the-art cancer biology-based mechanistic research integrated with a systems medicine approach:
1. Cancer biology-based mechanistic research incorporating a comprehensive range of model systems incorporating unique, pre-clinical and clinical resources and distinct phenotypic high content screen platforms.
2. A systems medicine approach with mathematical modelling to develop novel predictive/prognostic tools.
3. Centres of excellence in surgery, oncology and clinical trials, comprising clinical infrastructure and essential resources whereby candidate therapeutic targets and predictive/prognostic tools can be comprehensively evaluated, including accessing bio-repository resources.
We will train young scientists to apply multiple ‘omics’ technologies and approaches in model systems and systems biology to answer important clinically-relevant questions. Advances achieved will facilitate personalized targeted-medicine in treating lethal PC, and will impact beyond the scientific community by improving the well-being of advanced PC patients.
The TransPot scientific objective is to obtain an unmatched depth of molecular, mechanistic and informatics systems-level disease understanding in order to improve the prognosis and treatment of lethal PC, aimed to (i) provide important insights into molecular mechanisms driving treatment resistant PC including castrate-resistant PC (CRPC), (ii) identify novel therapeutic targets, (iii) develop and validate predictive models for disease progression, prognosis and responsiveness to current and novel (co-)treatment options, and (iv) provide superior, clinically relevant tools and biomarker signatures for personalising and optimising CRPC therapy.
Our research program is built on network-wide, state-of-the-art cancer biology-based mechanistic research integrated with a systems medicine approach:
1. Cancer biology-based mechanistic research incorporating a comprehensive range of model systems incorporating unique, pre-clinical and clinical resources and distinct phenotypic high content screen platforms.
2. A systems medicine approach with mathematical modelling to develop novel predictive/prognostic tools.
3. Centres of excellence in surgery, oncology and clinical trials, comprising clinical infrastructure and essential resources whereby candidate therapeutic targets and predictive/prognostic tools can be comprehensively evaluated, including accessing bio-repository resources.
We will train young scientists to apply multiple ‘omics’ technologies and approaches in model systems and systems biology to answer important clinically-relevant questions. Advances achieved will facilitate personalized targeted-medicine in treating lethal PC, and will impact beyond the scientific community by improving the well-being of advanced PC patients.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/721746 |
| Start date: | 01-01-2017 |
| End date: | 30-04-2021 |
| Total budget - Public funding: | 2 629 315,80 Euro - 2 629 315,00 Euro |
Cordis data
Original description
The Translational Research Network for Prostate Cancer (TransPot) program adopts an innovative, multidisciplinary approach, providing highly sought-after, effective solutions for incurable prostate cancer (PC).The TransPot scientific objective is to obtain an unmatched depth of molecular, mechanistic and informatics systems-level disease understanding in order to improve the prognosis and treatment of lethal PC, aimed to (i) provide important insights into molecular mechanisms driving treatment resistant PC including castrate-resistant PC (CRPC), (ii) identify novel therapeutic targets, (iii) develop and validate predictive models for disease progression, prognosis and responsiveness to current and novel (co-)treatment options, and (iv) provide superior, clinically relevant tools and biomarker signatures for personalising and optimising CRPC therapy.
Our research program is built on network-wide, state-of-the-art cancer biology-based mechanistic research integrated with a systems medicine approach:
1. Cancer biology-based mechanistic research incorporating a comprehensive range of model systems incorporating unique, pre-clinical and clinical resources and distinct phenotypic high content screen platforms.
2. A systems medicine approach with mathematical modelling to develop novel predictive/prognostic tools.
3. Centres of excellence in surgery, oncology and clinical trials, comprising clinical infrastructure and essential resources whereby candidate therapeutic targets and predictive/prognostic tools can be comprehensively evaluated, including accessing bio-repository resources.
We will train young scientists to apply multiple ‘omics’ technologies and approaches in model systems and systems biology to answer important clinically-relevant questions. Advances achieved will facilitate personalized targeted-medicine in treating lethal PC, and will impact beyond the scientific community by improving the well-being of advanced PC patients.
Status
CLOSEDCall topic
MSCA-ITN-2016Update Date
28-04-2024
Images
No images available.
Geographical location(s)
Search
Organisations
-
| UNIVERSITY OF GLASGOW (Coördinator)
-
| ALMAC DIAGNOSTIC SERVICES LIMITED
-
| AMIC - Queen's University Belfast (QUB)
-
| CANCER RESEARCH UK LBG
-
| Carver Wilde Communications Ltd
-
| ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
-
| European Association of Urology
-
| GenomeScan B.V.
-
| HELSINGIN YLIOPISTO
-
| IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON
-
| MOSAIQUES DIAGNOSTICS GMBH
-
| NUMARES AG
-
| Prostate Cancer UK
-
| TAMPEREEN KORKEAKOULUSAATIO SR
-
| TURUN YLIOPISTO (UTU)